Impact of coronavirus disease 2019 on patients with unresectable hepatocellular carcinoma treated with atezolizumab/bevacizumab

被引：0

作者：

Sang, Y. B. ^{[1
]}

Lee, C. R. ^{[2
]}

Kim, S-G. ^{[1
]}

Lee, B. ^{[3
]}

Kim, C. ^{[1
]}

Chon, H. J. ^{[1
]}

机构：

[1] CHA Bundang Med Ctr, Hematol & Oncol, Seongnam, South Korea

[2] CHA Bundang Med Ctr, Div Infect Dis, Dept Internal Med, Seongnam, South Korea

[3] Soonchunhyang Univ Hosp Seoul, Div Allergy & Resp Dis, Dept Internal Med, Seoul, South Korea

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

基金：

新加坡国家研究基金会;

关键词：

D O I：

10.1016/j.annonc.2023.10.772

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

193P

引用

页码：S1549 / S1550

页数：2

共 50 条

[31] Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
Vithayathil, Mathew
D'Alessio, Antonio
Fulgenzi, Claudia A. M.
Nishida, Naoshi
Schoenlein, Martin
von Felden, Johann
Schulze, Kornelius
Wege, Henning
Saeed, Anwaar
Wietharn, Brooke
Hildebrand, Hannah
Wu, Linda
Ang, Celina
Marron, Thomas U.
Weinmann, Arndt
Galle, Peter R.
Bettinger, Dominik
Bengsch, Bertram
Vogel, Arndt
Balcar, Lorenz
Scheiner, Bernhard
Lee, Pei-Chang
Huang, Yi-Hsiang
Amara, Suneetha
Muzaffar, Mahvish
Naqash, Abdul Rafeh
Cammarota, Antonella
Personeni, Nicola
Pressiani, Tiziana
Pinter, Matthias
Cortellini, Alessio
Kudo, Masatoshi
Rimassa, Lorenza
Pinato, David J.
Sharma, Rohini
LIVER INTERNATIONAL, 2022, 42 (11) : 2538 - 2547
[32] Impact of immune-related adverse events in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Suzuki, Keito
Yasui, Yutaka
Tsuchiya, Kaoru
Matsumoto, Hiroaki
Yamazaki, Yudai
Uchihara, Naoki
Tanaka, Yuki
Miyamoto, Haruka
Yamada-Shimizu, Michiko
Keitoku, Taisei
Okada, Risa
Higuchi, Mayu
Takaura, Kenta
Tanaka, Shohei
Maeyashiki, Chiaki
Tamaki, Nobuharu
Nakanishi, Hiroyuki
Takahashi, Yuka
Asahina, Yasuhiro
Okamoto, Ryuichi
Kurosaki, Masayuki
Izumi, Namiki
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 (06) : 1183 - 1189
[33] Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review
Ahmed, Faiza
Onwumeh-Okwundu, Jennifer
Yukselen, Zeynep
Endaya Coronel, Maria-Kassandra
Zaidi, Madiha
Guntipalli, Prathima
Garimella, Vamsi
Gudapati, Sravya
Mezidor, Marc Darlene
Andrews, Kim
Mouchli, Mohamad
Shahini, Endrit
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 13 (11) : 1813 - 1832
[34] Impact of renal function on the prognosis of patients receiving Atezolizumab/Bevacizumab combination therapy and Lenvatinib monotherapy for unresectable hepatocellular carcinoma
Takada, Hitomi
Yamashita, Koji
Osawa, Leona
Komiyama, Yasuyuki
Nakakuki, Natsuko
Muraoka, Masaru
Suzuki, Yuichiro
Sato, Mitsuaki
Takano, Shinichi
Fukasawa, Mitsuharu
Yamaguchi, Tatsuya
Maekawa, Shinya
Takahashi, Kazuya
Uchimura, Kohei
Enomoto, Nobuyuki
ONCOLOGY, 2023, 101 (10) : 609 - 623
[35] Variceal bleeding following treatment with atezolizumab plus bevacizumab in two patients with unresectable hepatocellular carcinoma
Matsui, Teppei
Nagai, Hidenari
Mukozu, Takanori
Wakui, Noritaka
Matsuda, Takahisa
Igarashi, Yoshinori
CLINICAL JOURNAL OF GASTROENTEROLOGY, 2024, : 1058 - 1066
[36] Usefulness of atezolizumab plus bevacizumab as second-line therapy for patients with unresectable hepatocellular carcinoma
Yamaba, Shinpei
Imai, Yukinori
Sugawara, Kayoko
Uchida, Yoshihito
Fuchigami, Akira
Uchiya, Hiroshi
Nakayama, Nobuaki
Mochida, Satoshi
PLOS ONE, 2024, 19 (04):
[37] Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review
Faiza Ahmed
Jennifer Onwumeh-Okwundu
Zeynep Yukselen
Maria-Kassandra Endaya Coronel
Madiha Zaidi
Prathima Guntipalli
Vamsi Garimella
Sravya Gudapati
Marc Darlene Mezidor
Kim Andrews
Mohamad Mouchli
Endrit Shahini
World Journal of Gastrointestinal Oncology, 2021, 13 (11) : 1813 - 1832
[38] Reply to: 'Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma'
de Franchis, Roberto
Bosch, Jaume
Garcia-Tsao, Guadalupe
Reiberger, Thomas
Ripoll, Cristina
JOURNAL OF HEPATOLOGY, 2022, 77 (02)
[39] Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
Rossari, F.
Tada, T.
Shimose, S.
Kudo, M.
Yoo, C.
Cheon, J.
Finkelmeier, F.
Lim, H. Y.
Presa, J.
Masi, G.
Bergamo, F.
Amadeo, E.
Vitiello, F.
Foti, S.
Persano, M.
Piscaglia, F.
Scartozzi, M.
Cascinu, S.
Rimini, M.
Gardini, A. Casadei
ANNALS OF ONCOLOGY, 2023, 34 : S1547 - S1547
[40] Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a real-world, multicenter study
Rossari, Federico
Tada, Toshifumi
Suda, Goki
Shimose, Shigeo
Kudo, Masatoshi
Yoo, Changhoon
Cheon, Jaekyung
Finkelmeier, Fabian
Lim, Ho Yeong
Presa, Jose
Masi, Gianluca
Bergamo, Francesca
Amadeo, Elisabeth
Vitiello, Francesco
Kumada, Takashi
Sakamoto, Naoya
Iwamoto, Hideki
Aoki, Tomoko
Chon, Hong Jae
Himmelsbach, Vera
Iavarone, Massimo
Cabibbo, Giuseppe
Montes, Margarida
Foschi, Francesco Giuseppe
Vivaldi, Caterina
Solda, Caterina
Sho, Takuya
Niizeki, Takashi
Nishida, Naoshi
Steup, Christoph
Hirooka, Masashi
Kariyama, Kazuya
Tani, Joji
Atsukawa, Masanori
Takaguchi, Koichi
Itobayashi, Ei
Fukunishi, Shinya
Tsuji, Kunihiko
Ishikawa, Toru
Tajiri, Kazuto
Ochi, Hironori
Yasuda, Satoshi
Toyoda, Hidenori
Ogawa, Chikara
Nishimura, Takashi
Hatanaka, Takeshi
Kakizaki, Satoru
Shimada, Noritomo
Kawata, Kazuhito
Hiraoka, Atsushi
LIVER CANCER, 2024,

← 1 2 3 4 5 →